Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07308964) titled 'Comparison of the Efficacy and Safety of 4 vs. 8 Treatments With Tepezza (Teprotumumab) for Thyroid Eye Disease' on Dec. 28, 2025.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Sheba Medical Center
Condition:
Thyroid Eye Disease
Thyroid Eye Disease, TED
Thyroid Eye Disease (TED)
Intervention:
Drug: Teprotumumab Injection [Tepezza]
Recruitment Status: Not recruiting
Phase: Phase 4
Date of First Enrollment: January 2026
Target Sample Size: 40
To know more, visit https://c...